Modulation of glial cells activation in Parkinson?s Disease model induced by Lipopolysaccharide (LPS)

RODRIGUEZ, GASPAR; NISHIDA, FABIAN; ANESETTI-NELLI, SOLEDAD; DOLCETTI, FRANCO JC; BELLINI, MJ; FALOMIR LOCKHART, EUGENIA; HEREÑU, CB

Mar del Plata

Congreso; XXXII Congress of the Argentine Society for Research in Neuroscience; 2017

Sociedad Argentina de Neurociencias (SAN)

Parkinson?s Disease (PD) is a progressive neurodegenerative disorder which manifests as a motor disorder, characterized by slowness of movements, rigidity and tremor. Motor dysfunction of PD is due to dopamine loss in the neostriatum and due to the neurodegeneration of dopaminergic neuron?s cell bodies of the Substantia Nigra pars Compacta (SNPC). Evidence suggests that chronic neuroinflammation, mediated by activated microglial and astroglial cells in the SNPC, could be essential for the degenerative process.It has been shown that intranigral LPS injection in rodents induces activation of glial cells, which release neurotoxic and pro-inflammatory factors that damage nigral dopaminergic neurons. Based on this evidence, our objectives were the following:-Generate a PD in vivo model by injecting LPS unilaterally in SNPC in order to characterize its impact on the motor function.-Implement gene therapy for IGF1 in order to evaluate its neurorestorative effect on rats? motor performance, on glial activation and on inflammatory response.Our results show that IGF1 gene therapy is capable of restoring motor deficit present on a PD model induced by LPS. Moreover, we observed a significant increment of both GFAP+ (astrocytes) and Iba1+ (microglia) cells on the ipsilateral hemisphere of rats injected with LPS, which was diminished by IGF1.In conclusion, IGF1 gene therapy can modulate glial activation and improve motor impairment caused by LPS injection.